News Updates

More Articles Back to Article

NICE backs Bayer's darolutamide combo for metastatic prostate cancer

The UK's National Institute for Health and Care Excellence has recommended Bayer's Nubeqa, or darolutamide, in tablet form as a treatment component with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer. NHS England and Bayer have an existing agreement granting clinicians the capability to gain early access, and NICE's latest decision will allow more eligible patients from England and Wales to obtain the medication. PMLive (UK) (5/22)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!